PhoeniX: A New Generation of Mammography Systems

At the heart of the award-winning project is PhoeniX, the groundbreaking technology developed by XIMED, introducing a true paradigm shift in breast imaging.

By leveraging X-ray phase contrast imaging within a compact, clinically integrable system, PhoeniX enables ultra-precise characterization of microcalcifications, often associated with carcinoma in situ lesions that can progress to invasive cancer if detected late.

i-Lab: A National Recognition and a Strategic Catalyst for XIMED

The i-Lab competition is a key accelerator for France’s deeptech startups.
By joining the winners of the 2025 edition, XIMED reaffirms the scientific, technological, and clinical robustness of its approach and benefits from the strategic support of the BpiFrance Deeptech label.

This application pursued a dual objective to demonstrate the scientific and clinical relevance of PhoeniX before a panel of leading experts; and to accelerate technological and industrial development toward seamless integration intro clinical practice.

A Breakthrough Innovation for Breast Cancer Diagnostics

The i-Lab jury was undoubtedly convinced by the tangible clinical impact of PhoeniX. By revealing structural details invisible to conventional imaging, the dual phase-contrast X-ray technology enables better tissue differentiation and a more reliable assessment of microcalcifications. This new generation of mammography systems aims to reduce unnecessary macrobiopsies and improve diagnostic confidence for healthcare professionals.

Building on this recognition, XIMED now plans to accelerate its R&D roadmap and strengthen partnerships with both hospitals and industry players.
The ambition: to transform PhoeniX into a certified, industrialized clinical system capable of becoming the new gold standard in mammography, in France and worldwide.

We would like to thank all our partners, shareholders, and the associations and networks XIMED is part of, as well as our entire team, for their continued support, trust and commitment : BPI France, Région Nouvelle-Aquitaine, IXCORE, IXCampus, ALPhANOV, Imagine Optic, Institut Bergonié, Laboratoire CELIA, Amplitude, Unitec, ALPHA-RLH, ALLISNA.

L’article XIMED – Winner of the 2025 BpiFrance i-Lab Competition est apparu en premier sur XIMED.

In recent weeks, XIMED has gained increased visibility within the MedTech ecosystem, thanks to specialized media coverage and recognition at leading industry events.
A committed player in the deeptech and MedTech sectors, XIMED develops and deploys a range of innovative products, such as BrightX and PhoeniX, designed to integrate seamlessly into the diagnostic and care pathway for breast cancer.

Growing recognition in the MedTech and radiology ecosystem

Leading media outlets, such as Tech Imago and Docteur Imago, have recently highlighted the relevance and impact of XIMED’s innovations in medical imaging, particularly in breast cancer diagnosis.

This targeted recognition is complemented by other media mentions:

As well as XIMED’s selection at the Inpho Venture Summit, demonstrating the growing interest in the company’s technological advancements.

This momentum was further reinforced by a double selection at the Journées Francophones de Radiologie (JFR 2025), a major event for medical imaging professionals.
XIMED participated both as an exhibitor at the Innovation Village and as a finalist for the Start-up Innovation Award, alongside the most promising companies in the field.
This recognition was granted by a jury of experts including representatives from the French Society of Radiology (SFR), Medicen Paris Region, the SNITEM, and the French Healthcare Association.

Visibility that strengthens a lasting presence in the ecosystem

These distinctions and media mentions represent a strong sign of institutional recognition and reinforce XIMED’s position as a leading innovator in medical technology, as well as a key player in the entrepreneurial ecosystem of Nouvelle-Aquitaine and the MedTech sector.

They also highlight the impact and relevance of XIMED’s solutions, which contribute to early breast cancer diagnosis while reducing the need for invasive procedures, often stressful for patients, time-consuming for healthcare professionals, and costly for healthcare systems.
Through its innovations, XIMED helps improve patient care pathways and optimize therapeutic strategy.

Beyond immediate recognition, this institutional and media visibility positions XIMED within a sustainable trajectory of excellence.
It demonstrates the company’s ability to bring together partners, hospitals, and industry stakeholders around a regional innovation in X-ray imaging, now recognized at a national level, and to assert its role in building a competitive, innovative, and health-focused medical and economic ecosystem.

L’article XIMED, the Medtech startup in the spotlight est apparu en premier sur XIMED.

XIMED participated as an exhibitor at the CHU HealthTech Connexion Day exhibition

L’article CHU HealthTech Connexion Day est apparu en premier sur XIMED.

XIMED TOP VC Selected start-ups by the European committee of INPHO SUMMIT.

L’article XIMED TOP VC Selected start-ups est apparu en premier sur XIMED.

L’article XIMED is hiring est apparu en premier sur XIMED.